Lipoti Latsopano Lokhudza Zizindikiro Za Usiku ndi Kugwira Ntchito Masana Kwa Akuluakulu Omwe Ali ndi Insomnia

A GWIRITSANI KwaulereKutulutsidwa 2 | eTurboNews | | eTN
Written by Linda Hohnholz

Idorsia Pharmaceuticals, US Inc. lero adalengeza kufalitsidwa kwa "Chitetezo ndi mphamvu ya daridoexant kwa odwala omwe ali ndi vuto la kusowa tulo: zotsatira za maulendo awiri a multicenter, randomized, double-blind, placebo controlled, phase 3" mu The Lancet Neurology.

Daridorexant 25 mg ndi 50 mg zotsatira zabwino za kugona, ndipo daridoexant 50 mg imathandizanso kugwira ntchito kwa masana, mwa anthu omwe ali ndi vuto la kusowa tulo, omwe ali ndi mbiri yabwino ya chitetezo. Chiwopsezo chonse chazovuta zoyipa chinali chofananira pakati pamagulu azachipatala mwa akulu ndi achikulire (azaka 65 ndi kupitilira) omwe ali ndi vuto la kusowa tulo. Monga momwe tafotokozera, daridoexant 50 mg inawonetsa kusintha kwakukulu m'mapeto oyambirira a kugona ndi kukonzanso komanso mapeto achiwiri a nthawi yonse ya kugona ndi kugona kwa masana.

Chofunika kwambiri, mayeserowo anali oyamba kufufuza zotsatira za chithandizo cha kusowa tulo pakugwira ntchito masana, pogwiritsa ntchito chida chovomerezeka cha zotsatira za odwala, chomwe chimaphatikizapo madera atatu osiyana (kuchenjeza / kuzindikira, maganizo, ndi kugona). Daridorexant 50 mg, yomwe inayesedwa mu imodzi mwa mayesero awiriwa, inawonetsa kusintha poyerekeza ndi zoyambira pamadera onse ogwira ntchito masana omwe ali ndi mlingo wapamwamba wokhazikika.

Emmanuel Mignot, MD, Pulofesa wa Psychiatry and Behavioral Sciences ku yunivesite ya Stanford ndi wolemba wamkulu, anati:

“Anthu amene ali ndi vuto la kusowa tulo nthawi zambiri amadandaula kuti amalephera kugwira ntchito masana. Iyi ndi nkhani yayikulu yomwe nthawi zambiri imanyalanyazidwa pochiza kusowa tulo ndipo kwenikweni mankhwala ambiri olimbikitsa kugona amatha kusokoneza kugwira ntchito kwa masana akakhala ndi zotsalira. Mu pulogalamuyi, sikuti tinangowona mphamvu ya daridoexant pakugona, kukonza komanso kuchuluka kwa tulo ndi khalidwe la odwala, koma chofunika kwambiri, pa mlingo wa 50 mg, pakugwira ntchito masana, makamaka mu malo ogona monga momwe amachitira scale, IDSIQ. Ogwira nawo ntchito mu gulu la daridoexant 50 mg adanenanso za kusintha kwazinthu zambiri za ntchito ya masana, monga momwe taonera ndi chida chatsopanochi komanso chovomerezeka chomwe chinayesa maganizo, tcheru / kuzindikira, ndi kugona. N’zosangalatsa kuona kuti vuto la kusowa tulo limaoneka ngati vuto la usiku komanso chifukwa cha kuvutika masana.”

Kuchita Bwino ndi Chitetezo Zotsatira

Daridorexant 50 mg imathandizira kwambiri kugona, kukonza tulo komanso kudziwonetsera nokha nthawi yogona pa mwezi umodzi ndi itatu poyerekeza ndi placebo. Mphamvu yayikulu kwambiri idawonedwa ndi mlingo wapamwamba kwambiri (50 mg), wotsatiridwa ndi 25 mg, pomwe mlingo wa 10 mg sunakhale ndi zotsatirapo zazikulu. M'magulu onse ochiritsira chiwerengero cha magawo ogona chinasungidwa, mosiyana ndi zomwe zinanenedwa ndi benzodiazepine receptor agonists.

Cholinga chachikulu cha mayeserowa chinali kuyesa zotsatira za daridoexant pakugwira ntchito masana kwa odwala omwe ali ndi vuto la kusowa tulo, monga momwe amachitira ndi Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). IDSIQ ndi chida chotsimikizika cha zotsatira za odwala chomwe chimapangidwa molingana ndi malangizo a FDA, kuphatikiza kuyika kwa odwala, kuyeza kugwira ntchito kwa masana kwa odwala omwe ali ndi vuto la kugona. Chiwerengero cha tulo cha IDSIQ chinawunikidwa ngati chomaliza chachiwiri mu maphunziro onse ofunikira komanso kufananitsa kwa placebo kumaphatikizapo kulamulira kuchulukitsa. Daridorexant 50 mg inawonetsa kusintha kwakukulu kwa chiwerengero cha kugona kwa masana pa mwezi umodzi ndi mwezi wa 3. Malo ogona ogona sanali bwino kwambiri pa 25 mg mu phunziro lililonse pa nthawi iliyonse. Daridorexant 50 mg inathandizanso zina zowonjezera za IDSIQ domain (chidziwitso / chidziwitso, domain domain) ndi chiwerengero chonse (p-values ​​<0.0005 motsutsana ndi placebo osasinthidwa kuti achuluke). Kusintha kwa magwiridwe antchito masana ndi daridoexant 50 mg pang'onopang'ono kumawonjezeka pa miyezi itatu ya phunzirolo.

Chiwopsezo chonse cha zochitika zoyipa zinali zofananira pakati pamagulu amankhwala. Zoyipa zomwe zimachitika mwa opitilira 5% mwa omwe adatenga nawo gawo anali nasopharyngitis ndi mutu. Panalibe kuwonjezeka kodalira mlingo pazochitika zovuta pamtundu uliwonse wa dosing, kuphatikizapo kugona ndi kugwa. Kupitilira apo, palibe kudalira, kusowa tulo kapena kukomoka komwe kunachitika pambuyo posiya chithandizo mwadzidzidzi. Pamagulu onse ochizira, zochitika zoyipa zomwe zimapangitsa kuti chithandizo chisiyidwe chinali pafupipafupi kwambiri ndi placebo kuposa daridoxant.

Martine Clozel, MD, ndi Chief Scientific Officer ku Idorsia, anati:

"Zidziwitso izi zofalitsidwa mu The Lancet Neurology zimasonyeza kuzama kwa umboni wopangidwa mu pulogalamu yachitukuko ya daridoexant ndi katundu wa mankhwala omwe ndimakhulupirira kuti amafotokoza zotsatira zake. Mankhwalawa adapangidwa kuti akhale ndi mphamvu pakugona koyambilira komanso kukonza pamiyeso yabwino kwambiri ndikupewa kugona kotsalira m'mawa. Mbiriyi, limodzi ndi kutsekeka kofanana kwa onse orexin receptors - zomwe zingayambitse kuletsa kwachisoni kulephera kugona - zitha kufotokozera kusintha komwe timawona pakugwira ntchito masana ndi 50 mg ya daridoxant. "

Daridoexant mu kusowa tulo

Matenda a kusowa tulo amadziwika ndi zovuta kuyambitsa kapena kusunga tulo ndipo amagwirizanitsidwa ndi kupsinjika maganizo kapena kuwonongeka kwa ntchito masana. Madandaulo osiyanasiyana a masana, kuyambira kutopa ndi kuchepa kwa mphamvu mpaka kusintha kwa malingaliro ndi zovuta zachidziwitso, zimanenedwa ndi anthu omwe ali ndi vuto la kugona.

Kusagona tulo kumayenderana ndi kudzuka mopitirira muyeso.

Daridorexant, wotsutsa wapawiri orexin receptor antagonist, adapangidwa ndikupangidwa ndi Idorsia pochiza kusowa tulo. Daridorexant imayang'ana kudzuka kwambiri kwa kusowa tulo poletsa ntchito ya orexin. Daridorexant imayang'ana makamaka dongosolo la orexin pomanga mopikisana ndi zolandilira zonse ziwiri, motero kutsekereza ntchito ya orexin.

Daridorexant ndi FDA yovomerezeka ku US pansi pa dzina la malonda QUVIVIQ™ ndipo ipezeka potsatira ndondomeko ya US Drug Enforcement Administration mu May 2022.

ZOMWE MUNGACHITE PA NKHANIYI:

  • In this program, not only did we see efficacy of daridorexant on sleep induction, maintenance and patient-reported sleep quantity and quality, but importantly, at the dose of 50 mg, on daytime functioning, notably in the sleepiness domain as measured with a new scale, the IDSIQ.
  • This profile, together with the equal blockade of both orexin receptors – which may lead to an inhibition of the chronic sympathetic hyperactivity characteristic of insomnia – may explain the improvement we see in daytime functioning with 50 mg of daridorexant.
  • A major focus of the trials was to evaluate the impact of daridorexant on daytime functioning in patients with insomnia, as assessed by the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).

<

Ponena za wolemba

Linda Hohnholz

Mkonzi wamkulu kwa eTurboNews zochokera ku eTN HQ.

Amamvera
Dziwani za
mlendo
1 Comment
zatsopano
Lakale
Zolowetsa Pamakina
Onani ndemanga zonse
1
0
Mukufuna malingaliro anu, chonde yankhani.x
Gawani ku...